LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Closed

4.1 -3.53

Buy Sell

Overview

Share price change

24h

Current

Min

4.1

Max

4.32

Key metrics
By Trading Economics
Income	5.5M -28M
Sales	8.2M 13M
EPS	-0.47
Profit margin	-208.694
Employees	172
EBITDA	8.7M -27M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+228.64% upside

Market Stats
By TradingEconomics
Market Cap	-12M 242M
Previous open	7.63
Previous close	4.1

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

18 gru 2025, 23:54 UTC

Hot Stocks

Stocks to Watch: Nike, Cassava Sciences, KB Home

18 gru 2025, 23:51 UTC

Earnings

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

18 gru 2025, 23:39 UTC

Major Market Movers

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

18 gru 2025, 22:57 UTC

Acquisitions, Mergers, Takeovers

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

18 gru 2025, 21:40 UTC

Earnings

Nike Sales Tick Up, But China Weakness Persists

18 gru 2025, 23:45 UTC

Market Talk

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

18 gru 2025, 23:37 UTC

Market Talk

Earnings

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

18 gru 2025, 23:36 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

18 gru 2025, 23:03 UTC

Acquisitions, Mergers, Takeovers

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

18 gru 2025, 23:02 UTC

Acquisitions, Mergers, Takeovers

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

18 gru 2025, 23:00 UTC

Acquisitions, Mergers, Takeovers

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

18 gru 2025, 22:59 UTC

Acquisitions, Mergers, Takeovers

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

18 gru 2025, 22:58 UTC

Acquisitions, Mergers, Takeovers

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

18 gru 2025, 22:57 UTC

Acquisitions, Mergers, Takeovers

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

18 gru 2025, 22:56 UTC

Acquisitions, Mergers, Takeovers

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

18 gru 2025, 22:55 UTC

Earnings

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 gru 2025, 21:59 UTC

Earnings

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 gru 2025, 21:50 UTC

Market Talk

Earnings

Tech, Media & Telecom Roundup: Market Talk

18 gru 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18 gru 2025, 21:35 UTC

Earnings

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

18 gru 2025, 21:31 UTC

Earnings

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 gru 2025, 21:15 UTC

Earnings

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

18 gru 2025, 21:15 UTC

Earnings

Nike 2Q Greater China Rev Down 17% >NKE

18 gru 2025, 21:15 UTC

Earnings

Nike 2Q EPS 53c >NKE

18 gru 2025, 21:15 UTC

Earnings

Nike 2Q Apparel Rev $3.91B >NKE

18 gru 2025, 21:15 UTC

Earnings

Nike 2Q Equipment Rev $550M >NKE

18 gru 2025, 21:15 UTC

Earnings

Nike 2Q N Amer Rev $5.63B >NKE

18 gru 2025, 21:15 UTC

Earnings

Nike 2Q Footwear Rev $7.66B >NKE

18 gru 2025, 21:15 UTC

Earnings

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

18 gru 2025, 21:15 UTC

Earnings

Nike 2Q Greater China Rev $1.42B >NKE

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

228.64% upside

12 Months Forecast

Average 14 USD 228.64%

High 25 USD

Low 8 USD

Based on 8 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.